A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussishepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 3, 2012, Pages 337-344

  Quiambao, Beatriz ^a   Van Der Meeren, Olivier ^b   Kolhe, Devayani ^c   Gatchalian, Salvacion ^d  

^a Department of Health   (Philippines)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c GlaxoSmithKline Pharmaceuticals Ltd   (India)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Booster; Combination vaccines; Immunogenicity; Polio; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; POLIOMYELITIS VACCINE; POLIORIX; UNCLASSIFIED DRUG; ZILBRIX;

ADVERSE OUTCOME; ANOREXIA; ANTIBODY TITER; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE CONVULSION; FEMALE; FEVER; FILIPINO; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOREACTIVITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VACCINATION;

EID: 84860376246     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.3.18630     Document Type: Article

References (13)

1. World Health Organization. Immunization policy. Global programme for vaccines and immunization. Expanded Programme on Immunization. Available from: http://whqlibdoc.who.int/hq/1995/WHO_EPI_GEN_95.03_Rev.1.pdf. Accessed 22 May 2011.
2. World Health Organization. WHO position paper on Haemophilus influenzae type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record). Wkly Epidemiol Rec 2006; 81:445-52; PMID:17124755
3. World Health Organization. Global Immunization Data. 2010 Dec; Available from: http://www.who.int/immunization_monitoring/Global_Immunization_Data. pdf Accessed 22 May 2011.
4. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007; 26:496-500; PMID:17529866; http://dx.doi.org/10.1097/ INF.0b013e31805d7f17
5. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt H-J, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006; 25:507-12; PMID:16732148; http://dx.doi.org/10.1097/ 01.inf.0000222413.47344.23
6. World Health Organization. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec 2006; 81:137-44; PMID:16673508
7. Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10- valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009; 28(Suppl):S97-108; PMID:19325452; http://dx.doi.org/10.1097/INF.0b013e318199f61b
8. Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev Vaccines 2008; 7:97-115; PMID:18251697; http://dx.doi.org/10.1586/14760584.7.1.97
9. Gatchalian S, Reyes M, Bermal N, Chandrasekaran V, Han HH, Bock HL, et al. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life. Hum Vaccin 2008; 4:60-6; PMID:18376148; http://dx.doi.org/10.4161/hv.4.1.5069
10. Gatchalian SR, Ramakrishnan G, Bock HL, Lefevre I, Jacquet JM. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children. Hum Vaccin 2010; 6:664-72; PMID:20657177; http://dx.doi.org/10.4161/ hv.6.8.12155
11. Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, et al & Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656-61; PMID:11547719; http://dx.doi.org/10.1056/NEJMoa003077
12. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68:650-60; PMID:7031583
13. World Health Organization. Standard Procedure for Determining Immunity to Poliovirus using the Microneutralisation Test. 1993 WHO/EPI/GEN 93 9.